EP3731853A4 - Verfahren zur behandlung von brustkrebs und chronischen erkrankungen - Google Patents

Verfahren zur behandlung von brustkrebs und chronischen erkrankungen Download PDF

Info

Publication number
EP3731853A4
EP3731853A4 EP18876846.9A EP18876846A EP3731853A4 EP 3731853 A4 EP3731853 A4 EP 3731853A4 EP 18876846 A EP18876846 A EP 18876846A EP 3731853 A4 EP3731853 A4 EP 3731853A4
Authority
EP
European Patent Office
Prior art keywords
breast cancer
chronic diseases
treating breast
treating
chronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18876846.9A
Other languages
English (en)
French (fr)
Other versions
EP3731853A1 (de
Inventor
Barry Hudson
Marc E. Lippman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Publication of EP3731853A1 publication Critical patent/EP3731853A1/de
Publication of EP3731853A4 publication Critical patent/EP3731853A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18876846.9A 2017-11-09 2018-11-08 Verfahren zur behandlung von brustkrebs und chronischen erkrankungen Withdrawn EP3731853A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762583910P 2017-11-09 2017-11-09
PCT/US2018/059855 WO2019094613A1 (en) 2017-11-09 2018-11-08 Method for treating breast cancer and chronic diseases

Publications (2)

Publication Number Publication Date
EP3731853A1 EP3731853A1 (de) 2020-11-04
EP3731853A4 true EP3731853A4 (de) 2021-12-01

Family

ID=66439265

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18876846.9A Withdrawn EP3731853A4 (de) 2017-11-09 2018-11-08 Verfahren zur behandlung von brustkrebs und chronischen erkrankungen

Country Status (3)

Country Link
EP (1) EP3731853A4 (de)
CA (1) CA3118711A1 (de)
WO (1) WO2019094613A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230048576A1 (en) * 2019-03-19 2023-02-16 City Of Hope Compounds for the treatment of neuropathic pain
CN115594642A (zh) * 2021-06-28 2023-01-13 广西医科大学（Cn） 阿齐瑞格三氮唑衍生物及其抗乳腺癌用途
US11648235B1 (en) 2022-12-30 2023-05-16 Cantex Pharmaceuticals, Inc. Treatment of glioblastoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
WO2008154638A2 (en) * 2007-06-12 2008-12-18 Board Of Regents, The University Of Texas System Antagonists of the receptor for advanced glycation end-products (rage)

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DHUMALE SUHASHINI S. ET AL: "Quercetin protects necrotic insult and promotes apoptosis by attenuating the expression of RAGE and its ligand HMGB1 in human breast adenocarcinoma cells : QUERCETIN PROTECTS NECROTIC INSULT AND PROMOTES APOPTOSIS", IUBMB LIFE, vol. 67, no. 5, 1 May 2015 (2015-05-01), pages 361 - 373, XP055850522, ISSN: 1521-6543, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fiub.1379> DOI: 10.1002/iub.1379 *
GANJU RAMESH K: "Receptor for Advanced Glycation End Products (RAGE) as a Novel Target for Inhibiting Breast Cancer Bone Metastasis PRINCIPAL INVESTIGATOR: DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited", 1 April 2013 (2013-04-01), XP055853322, Retrieved from the Internet <URL:https://apps.dtic.mil/sti/pdfs/ADA592353.pdf> [retrieved on 20211020] *
ISHIBASHI Y. ET AL: "Metformin Inhibits Advanced Glycation End Products (AGEs)-induced Growth and VEGF Expression in MCF-7 Breast Cancer Cells by Suppressing AGEs Receptor Expression via AMP-activated Protein Kinase", HORMONE AND METABOLIC RESEARCH, vol. 45, no. 05, 13 May 2013 (2013-05-13), DE, pages 387 - 390, XP055850890, ISSN: 0018-5043, Retrieved from the Internet <URL:http://dx.doi.org/10.1055/s-0032-1331204> DOI: 10.1055/s-0032-1331204 *
JOSEPH K P ET AL: "Soluble receptor for advanced glycation endproducts (sRAGE) effectively reduces tumor growth as a single agent and in combination with doxorubicin in a spontaneous mammary tumor model", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 114, no. 2, 8 June 2017 (2017-06-08), pages 251, XP085055635, ISSN: 0022-4804, DOI: 10.1016/J.JSS.2003.08.164 *
KWAK T ET AL: "Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis", ONCOGENE, vol. 36, no. 11, 26 September 2016 (2016-09-26), London, pages 1559 - 1572, XP055850529, ISSN: 0950-9232, Retrieved from the Internet <URL:https://www.nature.com/articles/onc2016324.pdf> DOI: 10.1038/onc.2016.324 *
LI HALI ET AL: "Therapeutic Effects of Matrine on Primary and Metastatic Breast Cancer", THE AMERICAN JOURNAL OF CHINESE MEDICINE, vol. 38, no. 06, 5 January 2010 (2010-01-05), US, pages 1115 - 1130, XP055853518, ISSN: 0192-415X, Retrieved from the Internet <URL:http://dx.doi.org/10.1142/S0192415X10008512> DOI: 10.1142/S0192415X10008512 *
NAKAMURA ET AL: "Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension", MICROVASCULAR RESEARCH, ACADEMIC PRESS, US, vol. 70, no. 3, 1 November 2005 (2005-11-01), pages 137 - 141, XP005140749, ISSN: 0026-2862, DOI: 10.1016/J.MVR.2005.10.002 *
PENGFEI YU ET AL: "Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-ÎoB signaling", CYTOTECHNOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 59, no. 3, 17 September 2009 (2009-09-17), pages 219 - 229, XP019747692, ISSN: 1573-0778, DOI: 10.1007/S10616-009-9225-9 *
SALVATORE BONGARZONE ET AL: "Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective", JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, no. 17, 19 May 2017 (2017-05-19), US, pages 7213 - 7232, XP055575572, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.7b00058 *
See also references of WO2019094613A1 *
SHAHINUL ALAM ET AL: "Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial", SAUDI JOURNAL OF GASTROENTEROLOGY, vol. 22, no. 1, 1 January 2016 (2016-01-01), pages 69, XP055333534, ISSN: 1319-3767, DOI: 10.4103/1319-3767.173762 *
WU JING ET AL: "Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression", ACTA PHARMACOLOGICA SINICA, vol. 31, no. 10, 1 October 2010 (2010-10-01), GB, pages 1367 - 1375, XP055853275, ISSN: 1671-4083, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012909/pdf/aps2010110a.pdf> DOI: 10.1038/aps.2010.110 *
ZHANG HE-FANG ET AL: "Protective effects of matrine against progression of high-fructose diet-induced steatohepatitis by enhancing antioxidant and anti-inflammatory defences involving Nrf2 translocation", FOOD AND CHEMICAL TOXICOLOGY, PERGAMON, GB, vol. 55, 4 January 2013 (2013-01-04), pages 70 - 77, XP028992288, ISSN: 0278-6915, DOI: 10.1016/J.FCT.2012.12.043 *

Also Published As

Publication number Publication date
EP3731853A1 (de) 2020-11-04
CA3118711A1 (en) 2019-05-16
WO2019094613A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
EP3641770A4 (de) Verfahren zur behandlung von krebs
EP3474841A4 (de) Verfahren zur behandlung von ar+-brustkrebs
EP3423488A4 (de) Verfahren zur behandlung von krebs
EP3630089A4 (de) Verfahren für eine krebstherapie
EP3288382A4 (de) Verfahren zur behandlung von krebs
EP3285773A4 (de) Kombinationstherapie zur behandlung von krebs
EP3678663A4 (de) Kombinationstherapie zur behandlung von krebs
EP3606531A4 (de) Verfahren zur behandlung von krebs
EP3405203A4 (de) Verfahren zur behandlung von krebs
EP3389634A4 (de) Verfahren zur behandlung von krebs
EP3440112A4 (de) Verfahren zur behandlung von krebs
EP3684420A4 (de) Verfahren zur behandlung von dreifach negativem brustkrebs
EP3442946A4 (de) Verfahren zur behandlung von krebs
EP3589659A4 (de) Verbindungen und verwendung zur behandlung von krebs
EP3389652A4 (de) Verfahren zur behandlung von krebs
EP3325006A4 (de) Verfahren zur behandlung von cd166-exprimierendem krebs
ZA201908539B (en) Method of treatment of cancer
EP3787625A4 (de) Verfahren zur behandlung von krebs
EP3894561A4 (de) Verfahren zur behandlung von krebs
EP3487999A4 (de) Verfahren zur behandlung von krebs
EP3697767A4 (de) Verbindungen und verwendung zur behandlung von krebs
EP3731853A4 (de) Verfahren zur behandlung von brustkrebs und chronischen erkrankungen
EP3781215A4 (de) Verfahren zur behandlung von krebs
EP3295949A4 (de) Topisches arzneimittel zur behandlung von brustkrebs und herstellungsverfahren dafür
EP3723765A4 (de) Verfahren zur behandlung von krebs

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200702

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20211029

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/16 20060101ALI20211025BHEP

Ipc: A61P 35/00 20060101ALI20211025BHEP

Ipc: A61K 45/06 20060101ALI20211025BHEP

Ipc: A61K 31/166 20060101ALI20211025BHEP

Ipc: A61K 31/4164 20060101AFI20211025BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220528